This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

GREGORY SHWARTZMAN, M.D.; GEORGE BAEHR, M.D.; W. Y. HOLLINGSWORTH, M.D.

Arch Intern Med. 1936;58(5):799-811.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The preparation of any standardized antitoxic serum of a reliable concentration depends on the possibility of measuring the antitoxic content of the serum in terms of its power to prevent specifically a biologic reaction to a definite amount of toxin. The lack of such a specific biologic phenomenon for the detection and measurement of the toxins derived, for instance from Bacillus typhosus, Meningococcus, Bacillus coli and Pfeiffer's bacillus, has served to delay the preparation of therapeutic serums of uniform potency. With serums such as the antimeningococcic serum, which are presumed to owe their therapeutic value to the presence of bactericidal properties, the possibility exists that the presence of undetermined amounts of antitoxin may explain the generally recognized variability in therapeutic efficacy.¹

The discovery by one of us (G. S.²) of the phenomenon of local cutaneous reactivity to bacterial filtrates has offered a new biologic reaction by means of . . . [Full Text PDF of this Article]

Author Affiliations
NEW YORK; Surgeon, United States Public Health Service DETROIT

From the Laboratories and the Medical Service of the Mount Sinai Hospital, New York; and the Charity Hospital, and the United States Marine Hospital, New Orleans.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?